{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:25:43Z","timestamp":1793157943217,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/P017339\/1"],"award-info":[{"award-number":["MR\/P017339\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["201477\/Z\/16\/Z"],"award-info":[{"award-number":["201477\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["204826\/Z\/16\/Z"],"award-info":[{"award-number":["204826\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005073","name":"Agency for Defense Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005073","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000769","name":"University of Oxford","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000690","name":"Research Councils UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000690","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["EP\/R013756\/1"],"award-info":[{"award-number":["EP\/R013756\/1"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.vaccine.2019.04.056","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:26:34Z","timestamp":1556583994000},"page":"6951-6961","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components"],"prefix":"10.1016","volume":"37","author":[{"given":"Sofiya","family":"Fedosyuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Merritt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Polo","family":"Peralta-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Laroudie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anilkumar","family":"Kangokar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M","family":"Warimwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Angell-Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6823-9750","authenticated-orcid":false,"given":"Sarah C","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Xenopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anissa","family":"Boumlic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5410-7562","authenticated-orcid":false,"given":"Alexander D","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.04.056_b0005","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1016\/j.vaccine.2017.04.085","article-title":"Rapid development of vaccines against emerging pathogens: the replication-deficient simian adenovirus platform technology","volume":"35","author":"Gilbert","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.056_b0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coi.2016.05.014","article-title":"Viral vectors as vaccine platforms: from immunogenicity to impact","volume":"41","author":"Ewer","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2019.04.056_b0015","doi-asserted-by":"crossref","unstructured":"Morris SJS, Sarah; Spencer, Alexandra J.; Gilbert, Sarah C. Simian adenoviruses as vaccine vectors. Future Virology. 2016;11(9):649-59.","DOI":"10.2217\/fvl-2016-0070"},{"issue":"4","key":"10.1016\/j.vaccine.2019.04.056_b0020","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1089\/hum.2014.007","article-title":"Challenges in manufacturing adenoviral vectors for global vaccine product deployment","volume":"25","author":"Vellinga","year":"2014","journal-title":"Hum Gene Ther"},{"issue":"8","key":"10.1016\/j.vaccine.2019.04.056_b0025","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/mt.2016.83","article-title":"Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants","volume":"24","author":"Afolabi","year":"2016","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.056_b0030","doi-asserted-by":"crossref","first-page":"e57726","DOI":"10.1371\/journal.pone.0057726","article-title":"Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults","volume":"8","author":"Ogwang","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vaccine.2019.04.056_b0035","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/infdis\/jis670","article-title":"First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)","volume":"207","author":"Baden","year":"2013","journal-title":"J Infect Dis"},{"issue":"32","key":"10.1016\/j.vaccine.2019.04.056_b0040","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.056_b0045","unstructured":"CanSinoBIO. Ad5-EBOV 2017 [Available from: <http:\/\/www.cansinotech.com\/homes\/article\/show\/45\/26.html> Accessed: [10\/12\/2018]."},{"issue":"12","key":"10.1016\/j.vaccine.2019.04.056_b0050","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1080\/21645515.2017.1383575","article-title":"Chimpanzee adenoviral vectors as vaccines for outbreak pathogens","volume":"13","author":"Ewer","year":"2017","journal-title":"Human Vacc Immunotherapeut"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2019.04.056_b0055","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0734-9750(02)00030-7","article-title":"Production of adenovirus vector for gene therapy","volume":"20","author":"Nadeau","year":"2003","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.vaccine.2019.04.056_b0060","unstructured":"Luitjens A, Lewis JA, inventors; Crucell Holland BV, assignee. Method for the production of adenoviral vectors. US patent number 10,041,049. 2011."},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2019.04.056_b0065","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1002\/jgm.503","article-title":"Development and optimization of an adenovirus production process","volume":"6","author":"Kamen","year":"2004","journal-title":"J Gene Med"},{"issue":"16","key":"10.1016\/j.vaccine.2019.04.056_b0070","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1089\/10430340260355338","article-title":"A new scalable method for the purification of recombinant adenovirus vectors","volume":"13","author":"Green","year":"2002","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2019.04.056_b0075","first-page":"13","article-title":"Scaleable purification of adenovirus vectors","volume":"434","author":"Konz","year":"2008","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2019.04.056_b0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.chroma.2015.11.037","article-title":"Rational development of two flowthrough purification strategies for adenovirus type 5 and retro virus-like particles","volume":"1426","author":"Nestola","year":"2015","journal-title":"J Chromatogr A"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.056_b0085","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/bit.24742","article-title":"Development of a platform process for adenovirus purification that removes human SET and nucleolin and provides high purity vector for gene delivery","volume":"110","author":"Riske","year":"2013","journal-title":"Biotechnol Bioeng"},{"issue":"6","key":"10.1016\/j.vaccine.2019.04.056_b0090","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/btpr.25","article-title":"Towards purification of adenoviral vectors based on membrane technology","volume":"24","author":"Peixoto","year":"2008","journal-title":"Biotechnol Prog"},{"issue":"4","key":"10.1016\/j.vaccine.2019.04.056_b0095","first-page":"353","article-title":"Bioprocess development for canine adenovirus type 2 vectors","volume":"20","author":"Fernandes","year":"2013","journal-title":"GeneTher"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.056_b0100","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/bit.24342","article-title":"Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors","volume":"109","author":"Cottingham","year":"2012","journal-title":"Biotechnol Bioeng"},{"issue":"6","key":"10.1016\/j.vaccine.2019.04.056_b0105","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2144\/000112993","article-title":"Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function","volume":"45","author":"Stanton","year":"2008","journal-title":"Biotechniques"},{"issue":"10","key":"10.1016\/j.vaccine.2019.04.056_b0110","doi-asserted-by":"crossref","first-page":"e0006870","DOI":"10.1371\/journal.pntd.0006870","article-title":"A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis","volume":"12","author":"Wang","year":"2018","journal-title":"PLoS NeglTrop Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.056_b0115","first-page":"145","article-title":"Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses","volume":"78","author":"Reyes-Sandoval","year":"2010","journal-title":"InfectImmun"},{"key":"10.1016\/j.vaccine.2019.04.056_b0120","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/1743-422X-10-349","article-title":"Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice","volume":"10","author":"Warimwe","year":"2013","journal-title":"Virol J"},{"issue":"7","key":"10.1016\/j.vaccine.2019.04.056_b0125","doi-asserted-by":"crossref","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.056_b0130","doi-asserted-by":"crossref","first-page":"30","DOI":"10.12665\/J111.Raghunath","article-title":"Best practices for optimization and scale-up of microfiltration TFF processes","volume":"11","author":"Raghunath","year":"2012","journal-title":"BioProcessing J"},{"issue":"115","key":"10.1016\/j.vaccine.2019.04.056_b0135","doi-asserted-by":"crossref","first-page":"115ra2","DOI":"10.1126\/scitranslmed.3002925","article-title":"Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species","volume":"4","author":"Colloca","year":"2012","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.056_b0140","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0042-6822(68)90121-9","article-title":"The polypeptides of adenovirus. I. evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12","volume":"36","author":"Maizel","year":"1968","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2019.04.056_b0145","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ab.2005.11.014","article-title":"Quantitation of adenovirus type 5 empty capsids","volume":"349","author":"Takahashi","year":"2006","journal-title":"Anal Biochem."},{"key":"10.1016\/j.vaccine.2019.04.056_b0150","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jpba.2014.07.037","article-title":"Development and qualification of a high sensitivity, high throughput Q-PCR assay for quantitation of residual host cell DNA in purification process intermediate and drug substance samples","volume":"100","author":"Zhang","year":"2014","journal-title":"J Pharm Biomed Anal"},{"issue":"12","key":"10.1016\/j.vaccine.2019.04.056_b0155","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/gb-2011-12-12-236","article-title":"Alu elements: know the SINEs","volume":"12","author":"Deininger","year":"2011","journal-title":"Genome Biol"},{"key":"10.1016\/j.vaccine.2019.04.056_b0160","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/ncomms1615","article-title":"The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody","volume":"2","author":"Douglas","year":"2011","journal-title":"Nat Commun."},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.056_b0165","doi-asserted-by":"crossref","first-page":"e55435","DOI":"10.1371\/journal.pone.0055435","article-title":"Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus","volume":"8","author":"Vitelli","year":"2013","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.vaccine.2019.04.056_b0170","doi-asserted-by":"crossref","first-page":"e96381","DOI":"10.1172\/jci.insight.96381","article-title":"Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions","volume":"2","author":"Payne","year":"2017","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.056_b0175","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/bit.20406","article-title":"Development of a novel adenovirus purification process utilizing selective precipitation of cellular DNA","volume":"91","author":"Goerke","year":"2005","journal-title":"Biotechnol Bioeng"},{"issue":"11","key":"10.1016\/j.vaccine.2019.04.056_b0180","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1089\/hum.2005.16.1346","article-title":"Serotype specificity of adenovirus purification using anion-exchange chromatography","volume":"16","author":"Konz","year":"2005","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2019.04.056_b0185","unstructured":"Weggeman M, Van Corven EJJM, inventors; Crucell Holland B.V. (Leiden, NL), assignee. Virus purification methods. US patent number 8,574,595. 2012"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19305328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19305328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:45:43Z","timestamp":1778737543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19305328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":37,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0264410X19305328"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.056","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}